9月15日，Illumina盘中上涨5.24%，报219.11美元/股，成交额1.45亿美元。
消息面上，瑞银近日将Illumina评级从中性大幅上调至买入，目标价从135美元跃升至260美元，远超此前分析师平均目标价193.61美元，释放强烈看多信号。与此同时，标普道琼斯指数公司此前宣布Illumina将于9月21日开盘前正式纳入标普500指数，被动指数基金的强制配置需求为股价提供额外买盘支撑。
基本面方面，公司二季度调整后每股收益1.31美元，超市场预期的1.23美元；营收11.59亿美元，同样超预期。RBC Capital Markets指出，Illumina临床测序收入有望维持两位数增长，竞争担忧正在消退。此外，公司董事会已授权15亿美元股票回购计划，进一步提振市场信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.